FDA Approves Tandem Diabetes Care’s G4 Insulin Pump
Tandem Diabetes Care said Wednesday that the FDA has approved its t:slim G4 touch screen insulin pump with continuous glucose monitoring integration.
The pump, designed for people 12 years and older, displays CGM graphs and trend information with current insulin delivery activity on the home screen to help patients and their doctors make informed treatment decisions. It combines features of Tandem’s pump technology with Dexcom’s CGM technology.
“The addition of t:slim G4 to our product family allows us to address a wider variety of diabetes management needs through the broadest range of insulin pump options available from one company,” said Kim Blickenstaff, Tandem’s president and CEO.
The company expects to begin shipping the pump to customers in October. — Michael Cipriano